NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding NeuBase Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 44 | 35 | −9 |
| Shares | 12.0M | 10.1M | −1.86M (−15.5%) |
| Value | $4.74M | $1.94M | −$2.80M (−59.0%) |
New holders (4)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ergoteles LLC | 37,899 | $7.21K | 0.00% |
| Susquehanna International Group, LLP | 37,891 | $7.21K | 0.00% |
| HRT Financial LP | 15,581 | $2.00K | 0.00% |
| Ritter Daniher Financial Advisory LLC | 2 | $0 | 0.00% |
Sold out (13)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AIGH Capital Management LLC | 872,023 | $345.0K |
| Sio Capital Management, LLC | 259,441 | $102.0K |
| Worth Venture Partners, LLC | 212,035 | $84.0K |
| Goldman Sachs Group Inc | 82,199 | $32.0K |
| Tocqueville Asset Management L.P. | 42,500 | $17.0K |
| Millennium Management LLC | 22,309 | $9.00K |
| Citadel Advisors LLC | 22,799 | $9.00K |
| Knightsbridge Asset Management, LLC | 20,212 | $8.00K |
| Oppenheimer & Co Inc | 15,750 | $6.00K |
| Jane Street Group, LLC | 14,156 | $6.00K |
| Heritage Wealth Advisors | 10,000 | $3.95K |
| JPMorgan Chase & Co | 25 | $0 |
| Simplex Trading, LLC | 171 | $0 |